Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03278379
Other study ID # 414-2016
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 15, 2017
Est. completion date September 20, 2021

Study information

Verified date March 2020
Source Sunnybrook Health Sciences Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 17
Est. completion date September 20, 2021
Est. primary completion date January 11, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (males or females), aged 18 years or older with pathologically confirmed, advanced (unresectable or metastatic) neuroendocrine tumour from a gastroenteropancreatic or lung source. Both participants with functional NETs and those with nonfunctional NETs shall be eligible for this study.

- Histologically confirmed, WHO Grade 2-3, well-differentiated NETs of gastroenteropancreatic or lung origin.

- Has received 0,1 or 2 prior lines of systemic therapy (chemotherapy, PRRT, targeted therapies such as everolimus or sunitinib). Somatostatin analogues are not considered a line of therapy for the purposes of this criterion.

- Radiological documentation of disease progression within 24 weeks of study enrolment. Disease progression must be demonstrated on two scans less than one year apart.

- Participants previously treated with any systemic therapies are eligible to enroll if disease progression is documented during or after their last treatment.

- Measurable disease as assessed by CT scan of the chest, abdomen and pelvis which is suitable for accurate repeated measurements (according to RECIST v1.1).

- ECOG performance status 0-2.

- Adequate bone marrow function (ANC > 1.5 x 109/L; Platelets >100 x109/L; haemoglobin > 90 g9/L).

- Adequate liver function defined by a total bilirubin level =1.5xULN and AST and ALT levels =2.5xULN for participants (or AST and ALT levels = 5xULN for participants with documented metastatic disease to the liver).

- Adequate renal function defined by an estimated creatinine clearance = 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).

- Willing and able to comply with all study requirements, including timing and/or nature of treatment and required assessments.

- Signed, written informed consent.

- Evidence of post-menopausal status, or negative urine or serum pregnancy test for female pre-menopausal participants (within approximately 14 days prior to enrolment). Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical explanation.

- Highly effective contraception for both male and female participants if the risk of conception exists (note: The effects of the IP on the developing human fetus are unknown; thus, women of childbearing potential and men able to father a child must agree to use 2 highly effective contraceptions, defined as methods with a failure rate of less than 1% per year. Highly effective contraception is required at least 28 days prior, throughout and for at least 60 days after avelumab treatment.)

Exclusion Criteria:

- Grade 1 NET or Grade 3 poorly-differentiated neuroendocrine carcinoma, or mixed adenoneuroendocrine carcinomas (MANEC)

- NETs confirmed to be from primaries other than the gastrointestinal tract, pancreas, or lung

- Prior use of PD-1, PD-L1 or CTLA-4 inhibitors

- Life expectancy of =3 months

- Concurrent treatment with other anticancer therapy (except somatostatin analogues for the purposes of functional control). Participants on somatostatin analogues for anti-proliferative therapy should have this therapy ceased, and would be eligible for enrolment if they have not received somatostatin analogues in the past 14 days.

- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent, with exception to:

- Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible

- Active infection requiring systemic therapy.

- History of primary autoimmunodeficiency

- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

- Prior organ transplantation, including allogeneic stem cell transplantation

- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

- Major surgery in the 2 weeks prior to randomization. Surgery with intent to debulk metastatic disease is allowed, as long as there is sufficient residual disease for RECIST measurements (see inclusion criteria 5).

- Participants with prior or concurrent malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, or any other cancer from which the patient has been disease free for three years.

- All participants with brain metastases and any of the following:

- They have not received local treatment to known brain metastases

- They have been clinically unstable in the 2 weeks prior to enrolment

- Requirement for treatment with systemic steroids exceeding the equivalent of 10mg oral prednisone per day

- Ongoing neurological symptoms related to brain metastases

- Leptomeningeal metastases

- Pregnancy, lactation, or inadequate contraception.

- Significant acute or chronic infections including, among others:

- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)

- Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive)

- Active tuberculosis

- Testing for these diseases is not mandatory unless clinically indicated.

- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade = 3)

- Persisting toxicity related to prior therapy of Grade >1 NCI-CTCAE v 4.03; however, alopecia, sensory neuropathy Grade = 2, or other Grade = 2 not constituting a safety risk based on investigator's judgment are acceptable.

- Known alcohol or drug abuse

- Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

- Any psychiatric condition that would prohibit the understanding or rendering of informed consent

- Vaccination within 4 weeks of the first dose of avelumab and while on trial, except for administration of inactivated vaccines

- Inability to obtain sufficient tumour tissue (whether archival or fresh) for PD-L1 testing. A core biopsy, endoscopic biopsy or surgical resection specimen shall be considered adequate tissue; a fine needle aspirate/biopsy will be considered insufficient tissue.

- Prior treatment for study indication with:

- Peptide Receptor Radiouclide Therapy (PRRT) administered within 3 months of enrolment

- Hepatic intra-arterial embolization, radio-frequency ablation, or cryoablation within 4 weeks of enrolment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Avelumab
Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .

Locations

Country Name City State
Canada Sunnybrook Health Sciences Centre Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Sunnybrook Health Sciences Centre Merck KGaA, Darmstadt, Germany

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation of PD-L1 status with response to avelumab Up to 2 years
Other Correlation of mutational load and T-cell repertoire analysis with response to avelumab Up to 2 years
Primary Overall response rate (ORR) The overall response rate will be defined as the number of participants with confirmed complete response or partial response (CR or PR) recorded as the best response over the study period, divided by the number of participants evaluable for response as defined by RECIST version 1.1. Up to 2 years
Secondary Disease control rate (DCR) The DCR will be defined as the number of patients with confirmed CR, PR or stable disease (SD) recorded as the best response over the study period, divided by the number of participants evaluable for response as defined by RECIST version 1.1. Up to 2 years
Secondary Duration of response Time from documentation of tumour response to disease progression Up to 2 years
Secondary Progression-free survival (PFS) PFS is defined as the time from first administration of study drug to the date of documented confirmed progression or death, whichever comes first Up to 2 years
Secondary Overall survival (OS) OS is defined as the time from first administration of drug to date of death. Up to 2 years
Secondary Rates of treatment-emergent adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 Up to 90 days after the last dose is administered
Secondary ORR by irRECIST version 1.1 Up to 2 years
Secondary DCR by irRECIST version 1.1 Up to 2 years
Secondary Duration of response by irRECIST version 1.1 Up to 2 years
Secondary PFS by irRECIST version 1.1 Up to 2 years
Secondary OS at 1 year 1 year
Secondary OS at 2 years 2 years
Secondary PFS at 1 year 1 year
Secondary PFS at 2 years 2 years
See also
  Status Clinical Trial Phase
Completed NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT02815969 - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Completed NCT02134639 - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation N/A
Completed NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Phase 2
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Terminated NCT01163526 - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies N/A
Completed NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors N/A
Completed NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase 3
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Active, not recruiting NCT04544098 - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Early Phase 1
Active, not recruiting NCT02736500 - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Phase 1/Phase 2